Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,013,442
  • Shares Outstanding, K 125,980
  • Annual Sales, $ 90,280 K
  • Annual Income, $ -66,340 K
  • 60-Month Beta N/A
  • Price/Sales 34.26
  • Price/Cash Flow N/A
  • Price/Book 5.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.24
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.46 +6.50%
on 03/28/19
25.53 -6.31%
on 04/05/19
+0.25 (+1.06%)
since 03/18/19
3-Month
22.46 +6.50%
on 03/28/19
29.94 -20.11%
on 01/25/19
-4.83 (-16.80%)
since 01/18/19

Most Recent Stories

More News
MorphoSys Nominates New Candidate for Supervisory Board

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 10, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that it has published its agenda for the Company's ordinary...

MOR : 23.92 (-2.53%)
MorphoSys to Present at Upcoming Investor Conferences

MUNICH, GERMANY / ACCESSWIRE / April 9, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conferences:

MOR : 23.92 (-2.53%)
Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations

PLANEGG/MUNICH GERMANY / ACCESSWIRE / April 1, 2019 / Dr. Sarah Fakih joined MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) as Vice President and Head of Corporate Communications...

MOR : 23.92 (-2.53%)
QGEN : 38.30 (-0.60%)
MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

PLANEGG/MUNICH GERMANY and SHANGHAI, China / ACCESSWIRE / March 19, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical...

MOR : 23.92 (-2.53%)
I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and German biopharma...

MOR : 23.92 (-2.53%)
MorphoSys Presents Results for Fiscal Year 2018

MOR : 23.92 (-2.53%)
NVS : 76.41 (-1.15%)
MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL

PLANEGG/ MUNICH, GERMANY / ACCESSWIRE / March 7, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today provided updates on L-MIND and B-MIND, its two ongoing clinical...

MOR : 23.92 (-2.53%)
Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; Nasdaq: MOR) will publish its Annual Financial Results 2018 on

MOR : 23.92 (-2.53%)
MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA Approval for Tremfya(R) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 27, 2019 / MorphoSys AG (FSE: MOR) (NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC (Janssen), has reported that the...

MOR : 23.92 (-2.53%)
MorphoSys to Present at Upcoming Investor Conference

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 21, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conference:

MOR : 23.92 (-2.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade MOR with:

Business Summary

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG...

See More

Key Turning Points

2nd Resistance Point 24.65
1st Resistance Point 24.29
Last Price 23.92
1st Support Level 23.72
2nd Support Level 23.51

See More

52-Week High 35.90
Fibonacci 61.8% 30.49
Fibonacci 50% 28.83
Fibonacci 38.2% 27.16
Last Price 23.92
52-Week Low 21.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar